Sex Differences in Minocycline-Induced Neuroprotection after Experimental Stroke | Zendy

Jun Li | Zendy; Louise D. McCullough | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sex Differences in Minocycline-Induced Neuroprotection after Experimental Stroke

Author(s) -

Jun Li,

Louise D. McCullough

Publication year - 2009

Publication title -

journal of cerebral blood flow and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.167

H-Index - 193

eISSN - 1559-7016

pISSN - 0271-678X

DOI - 10.1038/jcbfm.2009.3

Subject(s) - neuroprotection , minocycline , stroke (engine) , medicine , poly adp ribose polymerase , pharmacology , clinical trial , polymerase , biology , biochemistry , enzyme , mechanical engineering , engineering , antibiotics

Minocycline is neuroprotective in clinical and experimental stroke studies, due in part to its ability to inhibit poly (ADP-ribose) polymerase. Previous preclinical data have shown that interference with poly (ADP-ribose) polymerase signaling leads to sex-specific neuroprotection, reducing stroke injury only in males. In this study, we show that minocycline is ineffective at reducing ischemic damage in females after middle cerebral artery occlusion, likely due to effects on poly (ADP-ribose) polymerase signaling. Clinical trials must consider possible sex differences in the response to neuroprotective agents, if we hope to translate promising therapies to stroke patients of both sexes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research